APA (7th ed.) Citation

Mitsunaga, K., Bagot, M., Ram-Wolff, C., Guenova, E., von Gugelberg, C., Hodak, E., . . . Ortiz, P. (2024). Real-world study of pegylated interferon α-2a to treat mycosis fungoides/Sézary syndrome using time to next treatment as a measure of clinical benefit: An EORTC CLTG study. British journal of dermatology, 191(3), . https://doi.org/10.1093/bjd/ljae152

Chicago Style (17th ed.) Citation

Mitsunaga, Keila, et al. "Real-world Study of Pegylated Interferon α-2a to Treat Mycosis Fungoides/Sézary Syndrome Using Time to Next Treatment as a Measure of Clinical Benefit: An EORTC CLTG study." British Journal of Dermatology 191, no. 3 (2024). https://doi.org/10.1093/bjd/ljae152.

MLA (9th ed.) Citation

Mitsunaga, Keila, et al. "Real-world Study of Pegylated Interferon α-2a to Treat Mycosis Fungoides/Sézary Syndrome Using Time to Next Treatment as a Measure of Clinical Benefit: An EORTC CLTG study." British Journal of Dermatology, vol. 191, no. 3, 2024, https://doi.org/10.1093/bjd/ljae152.